

## 8-KA Filed April 23, 2009



## Introduction

This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2008, and subsequent SEC filings. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.





# **First Quarter Results**


(In millions, except per share data)

	3/	31/2008	3/	31/2009	+/(-)
Revenue	\$	1,103.2	\$	1,155.7	4.8%
Operating Income	\$	241.1	\$	240.4	-0.3%
<b>Operating Income Margin</b>		21.9%		20.8%	(110) bp
Diluted EPS	\$	1.14	\$	1.22	7.0%
<b>Operating Cash Flow</b>	\$	176.5	\$	208.9	18.4%
Less: Capital Expenditures	<u>\$</u>	37.9	<u>\$</u>	30.7	<u>-19.0%</u>
Free Cash Flow	\$	138.6	\$	178.2	28.6%





## **Cash Flow Trend**




Free Cash Flow

Operating Cash Flow

**10% OCF CAGR** 


aboratory Corporation of Americ

#### Revenue by Payer- US 2009 Q1 (In millions)





### Revenue by Business Area - US 2009 Q1 (In millions)







	YTD Q1-2007				YTD Q1-2008						YTD Q1-2009						
	Rever	nue				Revenue						Revent	ıe				
	\$'s	%	Accns	P	PPA	 \$'s	%	Accns		PPA	_	\$'s	%	Accns		PPA	
Client	\$ 254.4	25%	8.425	\$	30.19	\$ 285.4	27%	8.638	\$	33.04	\$	303.3	28%	8.918	\$	34.01	
Patient	97.0	10%	0.612	\$ 1	158.46	97.9	9%	0.590	\$	165.98		83.7	8%	0.531	\$	157.57	
Third Party																	
(Medicare/Medicaid)	184.8	19%	4.566	\$	40.47	198.8	19%	4.728	\$	42.05		220.3	20%	4.983	\$	44.21	
Managed Care:																	
- Capitated	44.0	4%	3.827	\$	11.50	42.4	4%	3.691	\$	11.49		44.6	4%	3.665	\$	12.16	
- Fee for service	418.5	42%	9.138	\$	45.80	 414.6	40%	9.339	\$	44.39		448.3	41%	9.584	\$	46.78	
Total Managed Care	462.5	46%	12.965	\$	35.67	 457.0	44%	13.030	\$	35.07		492.9	45%	13.249	\$	37.20	
LabCorp Total - US	\$ 998.7	100%	26.568	\$	37.59	\$ 1,039.1	100%	26.986	\$	38.51	\$	1,100.1	100%	27.681	\$	39.74	
LabCorp Total - Canada	\$ -	-	-		-	\$ 64.1	-	1.835	\$	34.90	\$	55.6	-	2.269	\$	24.50	
LabCorp Total	\$ 998.7		26.568	\$	37.59	\$ 1,103.2		28.821	\$	38.28	\$	1,155.7		29.950	\$	38.59	



#### Revenue by Business Area (in millions, except PPA)

	YTD Q1-2007				YTD Q1-2008						YTD Q1-2009					
	Revenue			Reven	ue					Reven	ue					
	\$'s	%	Accns	PPA		\$'s	%	Accns		PPA		\$'s	%	Accns		PPA
All Genomic	\$ 150.8	15%	2.091	\$ 72.15	\$	156.4	15%	2.144	\$	72.94	\$	172.4	16%	2.250	\$	76.64
Other Esoteric	109.3	11%	2.639	41.44		118.1	11%	2.881		40.98		140.2	13%	3.303		42.44
Histology	79.9	8%	0.668	119.63		79.2	8%	0.629		125.99		73.5	7%	0.609		120.69
All Genomic / Esoteric	340.1	34%	5.398	63.02		353.7	34%	5.654		62.55		386.1	35%	6.162		62.67
Core	658.5	66%	21.170	31.11		685.5	66%	21.332		32.13		714.0	65%	21.520		33.18
LabCorp Total - US	\$ 998.7	100%	26.568	\$ 37.59	\$	1,039.1	100%	26.986	\$	38.51	\$	1,100.1	100%	27.681	\$	39.74
LabCorp Total - Canada	\$ -	-	-	_	\$	64.1	-	1.835	\$	34.90	\$	55.6	-	2.269	\$	24.50
LabCorp Total	\$ 998.7	100%	26.568	\$ 37.59	\$	1,103.2		28.821	\$	38.28	\$	1,155.7		29.950	\$	38.59



## Financial Guidance - 2009

Excluding the impact of restructuring and other special charges and share repurchase activity after December 31, 2008, guidance for 2009 is:

• Revenue growth:	2-4%
• Diluted earnings per share:	\$4.75 to \$4.95
• Operating cash flow of approximately <sup>(1)</sup> :	\$800 million
Capital expenditures of approximately:	\$130 million

(1) Operating cash flow guidance excludes any transition payments to UnitedHealthcare and includes a \$54.8 million reduction due to required contributions to the Company's defined benefit retirement plan.



## Supplemental Financial Information

#### Laboratory Corporation of America Other Financial Information March 31, 2009 (\$ in million's)

	 Q1 09
Depreciation	\$ 31.8
Amortization	\$ 15.1
Capital expenditures	\$ 30.7
Cash flows from operations	\$ 208.9
Bad debt as a percentage of sales	5.32%
Effective interest rate on debt:	
Zero coupon-subordinated notes	2.00%
5 1/2% Senior Notes	5.38%
5 5/8% Senior Notes	5.75%
Term loan	3.67%
Revolving credit facility (weighted average)	0.97%
Days sales outstanding	52
UnitedHeathcare transition payments - Billed	\$ 5.5
UnitedHeathcare transition payments - Paid	\$ 5.5



